Syngene International Ltd (SYNGENE)
₹402.70
Mkt cap
₹16,256 Cr
P/E ratio
61.20
P/B
3.36
Div yield
0.31%
ROE
7.78%
ROCE
9.99%
EPS (TTM)
₹6.58
Book value
₹120
52W range
344–679
Sector
Healthcare
Price history
Previous close
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
NSE SYNGENEBSE 539268
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthModerate
TechnicalsBearish
52-week range
−40.69% from high₹403
₹344+16.91% from low₹679
Current
₹402.70
Prev close
₹398.60
Day
+1.03%
Price performance
1D
+1.10%
1W
+9.85%
1M
+9.75%
3M
+0.95%
6M
−6.75%
1Y
−39.05%
YTD
−38.84%
Financials
Revenue, profit & margin
P/E ratio
61.2×
SYNGENE is 104% above the sector median of 30.0×
SYNGENE61.2×
Sector median30.0×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 910 | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | 736 | 833 | |
| Expenses | 656 | 622 | 600 | 620 | 646 | 660 | 674 | 668 | 711 | 708 | 733 | 645 | 685 | |
| Operating Profit | 254 | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 | 209 | 303 | 91 | 147 | |
| OPM % | 28% | 27% | 35% | 22% | 27% | 30% | 34% | 24% | 22% | 23% | 29% | 12% | 18% | |
| Other Income | 14 | 26 | 16 | 50 | 16 | 18 | 19 | 18 | 15 | -55 | 16 | 12 | 21 | |
| Interest | 13 | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 | 12 | 12 | 10 | 10 | |
| Depreciation | 105 | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 | 114 | 112 | 112 | 112 | |
| Profit before tax | 151 | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 | 28 | 196 | -19 | 47 | |
| Tax % | 23% | 19% | 10% | 25% | 23% | 27% | 24% | 14% | 21% | 47% | 25% | -53% | 31% | |
| Net Profit | 116 | 112 | 189 | 76 | 106 | 131 | 183 | 87 | 67 | 15 | 148 | -9 | 32 | |
| EPS in Rs | 2.90 | 2.77 | 4.69 | 1.88 | 2.64 | 3.26 | 4.55 | 2.15 | 1.67 | 0.37 | 3.67 | -0.22 | 0.80 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.42% · closed higher next day 19 of last 42
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 26 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24 | 23 Oct '24◦ | 23 Jan '25◦ | 24 Apr '25 | 23 Jul '25 | 5 Nov '25◦ | 22 Jan '26◦ | 29 Apr '26◦ | 29 Jul '26◦ | 27 Oct '26◦ |
| Earnings day | −0.30% | −0.07% | +5.50% | +5.13% | −6.01% | −12.78% | +0.70% | −4.01% | −8.23% | +8.21% | −3.63% | +12.19% |
| +1 day | +4.60% | −0.27% | +4.97% | +4.54% | −9.63% | −15.89% | −0.92% | −4.68% | −17.36% | +10.46% | −6.84% | +8.85% |
| +5 days | +8.20% | −3.67% | +11.10% | +2.80% | −11.85% | −16.18% | +6.81% | +2.41% | −21.07% | +6.00% | −3.50% | — |
| +15 days | +11.37% | −1.21% | +11.42% | +0.71% | −17.08% | −13.85% | −2.49% | −1.01% | −26.59% | +6.87% | −4.53% | — |
| +30 days | +1.23% | +1.60% | +20.64% | +5.28% | −19.76% | −13.76% | −4.08% | +1.63% | −30.93% | +4.94% | −7.30% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 1.25 Per Share | 1.25 | 25 Jun '26 | 26 Jun '26 |
Shareholding
as of Sep 202652.59%Promoter
Promoters52.59%
FIIs10.13%1.69
DIIs29.31%1.30
Public7.55%0.40
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹402.70 | 61.15 | 16,256 | 0.31% | 32 | −45.17% | 833 | −8.55% | 9.99% |
| Indegene | ₹586.80 | 33.16 | 14,141 | 0.38% | 112 | +9.99% | 1,122 | +39.55% | 18.82% |
| Suven Life Scie. | ₹258.85 | — | 7,314 | 0.00% | −128 | −147.69% | 4 | +90.91% | −79.54% |
| Vimta Labs | ₹484.90 | 26.60 | 2,168 | 0.41% | 21 | +3.46% | 112 | +9.95% | 25.23% |
| Fabtech Tech. | ₹123.90 | 18.50 | 551 | 0.48% | 15 | −67.06% | 92 | −24.19% | 13.88% |
| Novelix Pharma. | ₹68.57 | 53.93 | 195 | 0.00% | 1 | +972.73% | 37 | +65.15% | 10.87% |
| Bilcare | ₹75.33 | 8.91 | 177 | 0.00% | 15 | +473.06% | 226 | +21.20% | 7.06% |
| Median: 9 Co. | ₹123.90 | 29.95 | 551 | 0.00% | 15 | +9.99% | 92 | +30.38% | 10.87% |
Filings
Annual reports12
Concall transcripts86
PPTOct 2026RECOct 2026TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptApr 2026PPTApr 2026RECApr 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025PPTSep 2025TranscriptJul 2025PPTJul 2025TranscriptApr 2025RECApr 2025PPTMar 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 OctAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 28 Oct - Audio recording of Syngene’s Q2 FY27 earnings call uploaded on October 28, 2026.Announcement under Regulation 30 (LODR)-Investor Presentation 27 OctAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 27 Oct - Q2 FY27 revenue rose 13% sequentially; CFO Deepak Jain to exit; Bayview biologics got first manufacturing agreement.Announcement under Regulation 30 (LODR)-Change in Management 27 Oct - CFO Deepak Jain to exit; Ajay Tandon resigns Oct 30, 2026; two executives moved to Non-SMP.